Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep;42(17-18):1761-1789.
doi: 10.1002/elps.202100032. Epub 2021 May 27.

Chiral separation in the class of proton pump inhibitors by chromatographic and electromigration techniques: An overview

Lajos Attila Papp  1 , Gabriel Hancu  1 , Hajnal Kelemen  1 , Gergő Tóth  2
Affiliations
Review

Chiral separation in the class of proton pump inhibitors by chromatographic and electromigration techniques: An overview

Lajos Attila Papp et al. Electrophoresis. 2021 Sep.

Abstract

Proton pump inhibitors (PPIs) are benzimidazole-derivative chiral sulfoxides, frequently used in the treatment of gastric hyperacidity-related disorders. Due to their stereoselective metabolism, the eutomeric forms of PPIs can present a more advantageous pharmacokinetic profile by comparison with the distomers or racemates. Moreover, two representatives of the class are used in therapy both as racemates and as pure enantiomers (esomeprazole, dexlansoprazole). A relatively large number of enantioseparation methods employed for the stereoselective determination of PPIs from pharmaceutical, biological, and environmental matrices were published in the past three decades. The purpose of the current overview is to provide a systematic survey of the available chiral separation methods published since the introduction of PPIs in the therapy up to the present. Analytical and bioanalytical methods using different chromatographic and electromigration techniques reported for the enantioseparation of omeprazole, lansoprazole, pantoprazole, rabeprazole, ilaprazole, and tenatoprazole are included. The analytical conditions of the presented methods are summarized in three comprehensive tables, while a critical discussion of the applied techniques, possible mechanism of enantiorecognition, and future perspectives on the topic are also presented.

Keywords: Chiral separation; Chromatography; Electrophoresis; Pharmaceutical analysis; Proton pump inhibitors.

PubMed Disclaimer

References

7 References

    1. Wermuth, C. G., in: Wermuth, C., Aldous, D., Raboisson, P., Rognan, D. (Eds.), The Practice of Medicinal Chemistry, 4th ed., Elsevier, Amsterdam 2015, pp. 429-447.
    1. Agranat, I., Caner, H., Caldwell, J., Nat. Rev. Drug Discovery 2002, 1, 753-768.
    1. Agranat, I., Wainschtein, S. R., Zusman, E. Z., Nat. Rev. Drug Discovery 2012, 11, 972-973.
    1. Calcaterra, A., D'Acquarica, I., J. Pharm. Biomed. Anal. 2018, 147, 323-340.
    1. U. S. Food and Drug Administration (FDA), CDER New Drugs at FDA: CDER's New Molecular Entities and New Therapeutic Biological Products, https://www.fda.gov/drugs/development-approval-process-drugs/newdrugs-fd... [accessed Jan 20, 2021].

Publication types

LinkOut - more resources